BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.65) by 12.31 percent. This is a 83.87 percent decrease over losses of $(0.31) per share from the same period last year.
BioXcel Therapeutics Q3 EPS $(0.57) Beats $(0.65) Estimate
BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.65) by 12.31 percent. This is a 83.87 percent decrease over losses of $(0.31) per share
Benzinga · 11/14/2019 12:13